HRS-2189 Tablets
Sponsors
Shandong Suncadia Medicine Co., Ltd., Jiangsu HengRui Medicine Co., Ltd.
Conditions
Advanced Malignant TumorBreast CancerProstate Cancer
Phase 1
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
NCT05851092
Start: 2023-05-26End: 2025-12-31Target: 60Updated: 2023-07-07
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
RecruitingNCT06568094
Start: 2024-09-25End: 2027-06-01Target: 100Updated: 2026-09-17
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
RecruitingNCT06974929
Start: 2025-05-22End: 2026-12-01Target: 80Updated: 2026-06-12